PFE News & Events

Pfizer announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating Lorbrena versus Xalkori in people with previously untreated, anaplastic lymphoma kinase-positive advanced or metastatic non-small cell lung cancer, NSCLC. At seven years, patients treated with Lorbrena had a 55% likelihood of remaining alive without disease progression compared to 3% in the Xalkori treatment arm. Further, an updated analysis at seven years of median follow-up showed that investigator-assessed median progression-free survival, PFS, had not been reached with Lorbrena, with an estimated Hazard Ratio of 0.19, representing an 81% reduction in the risk of disease progression or death compared to Xalkori. Full results from the analysis will be presented today in an oral presentation at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting and simultaneously published in Annals of Oncology.

Pfizer (PFE) and Innovent Biologics (IVBXF) announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new breakthrough early-stage and de novo cancer medicines. The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates with novel differentiated payloads and multi-specific antibodies with differentiated immune-engaging features and unique designs. The agreement spans a portfolio of 12 programs comprising eight Innovent-originated early-stage programs and four Pfizer-proposed discovery programs. The companies will co-develop and share costs for select programs as they advance these programs through clinical development. According to the agreement, Innovent will conduct development of these programs through Phase 1, powered by its proprietary discovery engine and robust early clinical capabilities, after which Pfizer will lead future global development. The agreement also sets out the following licensing and commercialization structure: Pfizer will receive an exclusive global license for four programs, and will be responsible for the global development costs; Pfizer will receive an exclusive license outside Greater China for four programs, and will be responsible for the majority of the development costs; and Pfizer and Innovent will co-develop four programs globally and share the development costs. The companies will co-commercialize in the United States and Europe, and share the profits. Innovent will retain Greater China rights to these programs. Under the financial terms of the agreement, Innovent will receive a $650M upfront payment and is eligible for up to $9.85B in development, regulatory and commercial milestone payments. Additionally, Innovent will receive up to double-digit royalties on sales of each licensed product if approved. For the 'co-developed, co-commercialized' programs, the two companies will share the profits in the U.S. and Europe. The transaction is expected to close in the third quarter subject to fulfillment of required regulatory approvals.